RE: Blue finish29 Jul 2020 18:08
It is very exciting the closer we get to Septembers results. This from a previous RNS (as long as all above board seeing as it was DICK Darsteadly and MUTLEY at the helm) but gives you tingles all the same -
Dr Satu Vainikka, CEO of ValiRx, commented: "Successfully reaching the endpoints in VAL201 clinical studies and receiving the approval for the acceleration of the trial and to substantially escalate the dose, is a pivotal and substantial breakthrough for our lead compound. Since VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted, we anticipate that by increasing the dosage we will be able to see further anti-cancer activity. This accelerated study will speed-up the human development of the compound and by doing so, it will save both time and money. Most importantly, this potential treatment will more speedily meet the needs of those patients currently under-served by existing therapies. The pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena. We are entering a new and very exciting phase, which should result in the crystallisation of substantial value".
And then this for 301 and The Japanese Pharma too. Also, i have just found, 2 months before this report came to light our Japanese patent was acquired -
VAL201 has the potential to target hormone induced oncological conditions and abnormal growths, including prostate, breast and ovarian cancers as well as endometriosis. VAL201 is currently in Phase I/II clinical trials at UCLH for prostate cancer. The compound has also shown effects against Endometriosis in pre-clinical studies. The VAL201 treatment is differentiated from current advanced prostate cancer therapies, by not including complete and general androgen hormone deprivation.
The molecule is a peptide that inhibits the interaction between the androgen receptor and/or the oestrogen receptor complex with Src Kinase complex Domain 3. This very specific mode of action has been shown in pre-clinical studies to provide a potent therapeutic benefit with fewer side effects compared to the standard hormone therapy. VAL201 is potentially and uniquely able to treat prostate cancer without many of the other debilitating side effects associated with other therapies.
The Prostate cancer market is expected to rise to $8.2 billion in 2023 and the endometriosis market to $2billion by 2025. (Global Data)
Sign In
Follow the stocks
